Home › Stories › Stocks
🟢 Real move

Moderna's cancer vaccine data just doubled the stock

A Phase 3 melanoma win with Merck triggered a historic short squeeze.

Buzz velocity9.0×

What's happening

Moderna and Merck reported the first positive Phase 3 result for an mRNA neoantigen cancer therapy in melanoma, and the stock responded immediately — Decrypt and Ars Technica both confirm the trial success, while Yahoo Finance reports the stock surged as much as 160%, roughly doubling, with at least one analyst upgrade on the back of the data.

The numbers

Only 9 recent mentions and breadth of 2, but the price move dwarfs the chatter volume: a 160% surge described as burning short sellers out of a reported $5 billion in losses.

Our read

Real, and not close. Low chatter breadth is irrelevant here — the signal is in the price, and a mega-cap biotech doubling on a single trial readout with named short-seller losses is about as confirmed as this gets. Watch for Merck's own confirmation language and whether the melanoma result extends to other cancer types, since that's what decides if this holds or fades like past mRNA-pipeline spikes.

Sources we checked

See today's live board

This story is frozen as published on October 6, 2026. The live board shows what is moving right now, scored against real money.

Open this story live → See today's live board

Earlier on Moderna

More Stocks stories

Research, not financial advice. Sort Brick reports what its data showed at the time of publication. It is not a recommendation to buy or sell anything — you decide.

Get Sort Brick Daily - free, every evening

One short email every evening: what really moved, what was only noise, and what we logged first, with the times. Free. Information, not investment advice.

No spam. One click to unsubscribe. Sent by Sort Brick.